Showing 1971-1980 of 2105 results for "".
- Investigational Nonsteroidal Edaslonexent Treatment for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/investigational-nonsteroidal-edaslonexent-treatment-for-duchenne-muscular-dystrophy/2469205/Treatment of boys with Duchenne Muscular Dystrophy (DMD), age 4 to 7 years and never been exposed to steroids (n=31), led to growth patterns that were similar to children without DMD. Although the boys' growth rates were age normative, weight increase was less than the mean for boys at this a
- Head Sensors to Measure Frequency and Severity of Head Impact Have High Rate of False Positiveshttps://practicalneurology.com/news/head-sensors-to-measure-frequency-and-severity-of-head-impact-have-high-rate-of-false-positives/2469187/Concussion risk in young athletes has prompted researchers to use a variety of head impact sensors to measure frequency and severity of impacts during sports. A new study from Children's Hospital of Philadelphia (CHOP) shows these head sensors can record a large number of false positive impac
- Daytime Sleepiness in People Over Age 65 May Be at Risk for Medical Conditionshttps://practicalneurology.com/news/daytime-sleepiness-in-people-over-age-65-may-be-at-risk-for-medical-conditions/2469179/According to a preliminary study, people over age 65 who experience daytime sleepiness may be at risk of developing medical conditions such as diabetes, cancer, and high blood pressure. The study involved 10,930 participants and researchers interviewed participants over the phone twice, 3 years a
- FDA Approves Rimegepant for Acute Treatment of Migraine in Adultshttps://practicalneurology.com/news/fda-approves-rimegepant-for-acute-treatment-of-migraine-in-adults/2469170/The Food and Drug Administration (FDA) has approved rimegepant (Nurtec; Biohaven, New Haven, CT) for the acute treatment of migraine in adults. Rimegepant is administered as a fast-acting orally disintegrating table and a single dose of 75 mg provides pain relief within 1 hour. Rimegepant also ha
- Health Factors in 20s May Predict Cerebrovascular Disease and Dementia Later in Lifehttps://practicalneurology.com/news/health-factors-in-20s-may-predict-cerebrovascular-disease-and-dementia-later-in-life/2469168/Results from a preliminary study show that the presence of smoking, high cholesterol, or high body mass index (BMI) in a person's 20s may make them more likely to have cerebrovascular disease and dementia later in life. In the study, 189 people, mean age 24, were followed for 30 yea
- FDA Approves Expanded Indication for Vigabatrinhttps://practicalneurology.com/news/fda-approves-expanded-indication-for-vigabatrin/2469139/The Food and Drug Administration has approved expanded indications on the label for vigabatrin (Sabril, Lundbeck, Deerfield, IL) to treat refractory complex partial seizures in individuals age 2 to 10 years. This new label expansion now means there will be no age gap for individuals needing criti
- Sleep Deprivation May Increase Serum Tau Levelshttps://practicalneurology.com/news/sleep-deprivation-may-increase-serum-tau-levels/2469128/A preliminary study published in Neurology, has found that when young, healthy men were deprived of just 1 night of sleep, they had higher levels of tau in their blood than when they had a full, uninterrupted night of rest. In the study, participants had an average 17% increase in
- Mixed Martial Artists and Boxers Show Different Effects From Head Injurieshttps://practicalneurology.com/news/mixed-martial-artists-and-boxers-show-different-effects-from-head-injuries/2469120/A new study shows different effects in the brain for younger current fighters compared with older, retired fighters. The study is published in the December 23, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology. Both the current and former fighters ha
- FDA Approves Lemborexant For Treatment of Insomnia in Adultshttps://practicalneurology.com/news/fda-approves-lemborexant-for-treatment-of-insomnia-in-adults/2469116/The Food and Drug Administration (FDA) approved lemborexant (Dayvigo, Eisai, Woodcliff Lake, NJ) for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. In clinical trials, participants age 18 years or more with insomnia treated with lemb
- Perampanel Treatment for Partial-Onset and Secondary Generalized Tonic-Clonic Seizures Provides Durable Reduction in Seizure Frequency in Phase 3 and Phase 4 Trialshttps://practicalneurology.com/news/perampanel-treatment-for-partial-onset-seizures-and-generalized-tonic-clonic-seizures-provides-durable-reduction-in-seizure-frequency-in-phase-3-and-phase-4-trials/2469105/In the FREEDOM study (NCT03201900), a phase 3 open-label study, perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) was used as monotherapy to treat study participants, age 12 years or more, who were newly diagnosed with partial-onset sei